Literature DB >> 26629280

Viekira Pak (Ombitasvir, Paritaprevir, and Ritonavir Tablets; Dasabuvir Tablets): All-Oral Fixed Combination Approved for Genotype 1 Chronic Hepatitis C Infection.

Lisa A Raedler.   

Abstract

Entities:  

Year:  2015        PMID： 26629280      PMCID： PMC4665049     

Source DB:  PubMed          Journal:  Am Health Drug Benefits        ISSN： 1942-2962


× No keyword cloud information.
  15 in total

Review 1.  The global burden of hepatitis C.

Authors:  Daniel Lavanchy
Journal:  Liver Int       Date:  2009-01       Impact factor: 5.828

Review 2.  Direct-acting antiviral agents for hepatitis C virus infection.

Authors:  Jennifer J Kiser; Charles Flexner
Journal:  Annu Rev Pharmacol Toxicol       Date:  2012-11-05       Impact factor: 13.820

3.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

Review 4.  Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents.

Authors:  F Poordad; D Dieterich
Journal:  J Viral Hepat       Date:  2012-07       Impact factor: 3.728

Review 5.  Chronic hepatitis C: an age wave of disease burden.

Authors:  John G McHutchison; Bruce R Bacon
Journal:  Am J Manag Care       Date:  2005-10       Impact factor: 2.229

6.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Authors:  Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

7.  Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression.

Authors:  Gary L Davis; Miriam J Alter; Hashem El-Serag; Thierry Poynard; Linda W Jennings
Journal:  Gastroenterology       Date:  2009-10-25       Impact factor: 22.682

8.  Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

Authors:  Stefan Zeuzem; Ira M Jacobson; Tolga Baykal; Rui T Marinho; Fred Poordad; Marc Bourlière; Mark S Sulkowski; Heiner Wedemeyer; Edward Tam; Paul Desmond; Donald M Jensen; Adrian M Di Bisceglie; Peter Varunok; Tarek Hassanein; Junyuan Xiong; Tami Pilot-Matias; Barbara DaSilva-Tillmann; Lois Larsen; Thomas Podsadecki; Barry Bernstein
Journal:  N Engl J Med       Date:  2014-04-10       Impact factor: 91.245

Review 9.  Current prospects for interferon-free treatment of hepatitis C in 2012.

Authors:  Catherine A M Stedman
Journal:  J Gastroenterol Hepatol       Date:  2013-01       Impact factor: 4.029

10.  Current and future disease progression of the chronic HCV population in the United States.

Authors:  Martin Zalesak; Kevin Francis; Alex Gedeon; John Gillis; Kyle Hvidsten; Phyllis Kidder; Hong Li; Derek Martyn; Leslie Orne; Amanda Smith; Ann Kwong
Journal:  PLoS One       Date:  2013-05-21       Impact factor: 3.240
View more
  49 in total

1.  Viekira Pak (Ombitasvir, Paritaprevir, and Ritonavir Tablets; Dasabuvir Tablets): All-Oral Fixed Combination Approved for Genotype 1 Chronic Hepatitis C Infection.

Authors:  Lisa A Raedler
Journal:  Am Health Drug Benefits       Date:  2015-03

2.  Effects of Mild and Moderate Renal Impairment on Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir, and Ribavirin Pharmacokinetics in Patients with Chronic HCV Infection.

Authors:  Akshanth R Polepally; Prajakta S Badri; Doerthe Eckert; Sven Mensing; Rajeev M Menon
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-04       Impact factor: 2.441

3.  Treatment of Chronic Hepatitis C Infection with Sofosbuvir-Based Regimens in a Commercially Insured Patient Population.

Authors:  John Barron; Yiqiong Xie; Sze-Jung Wu; Jeff White; Joseph Singer; Bernard Tulsi; Alan Rosenberg
Journal:  Am Health Drug Benefits       Date:  2016-09

4.  Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Hepatitis C Virus-Infected Cirrhotic and Non-cirrhotic Patients: Analyses Across Nine Phase III Studies.

Authors:  Sathej Gopalakrishnan; Sven Mensing; Rajeev M Menon; Jiuhong Zha
Journal:  Clin Pharmacokinet       Date:  2018-11       Impact factor: 6.447

5.  Hepatic Pharmacokinetics and Pharmacodynamics With Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir Treatment and Variable Ribavirin Dosage.

Authors:  Andrew H Talal; Emily O Dumas; Barbara Bauer; Richard M Rejman; Andrew Ocque; Gene D Morse; Danijela Lucic; Gavin A Cloherty; Jennifer King; Jiuhong Zha; Hongtao Zhang; Daniel E Cohen; Nancy Shulman; Jean-Michel Pawlotsky; Christophe Hézode
Journal:  J Infect Dis       Date:  2018-01-17       Impact factor: 5.226

6.  Pharmacokinetics and tolerability of paritaprevir, a direct acting antiviral agent for hepatitis C virus treatment, with and without ritonavir in healthy volunteers.

Authors:  R M Menon; C E Klein; T J Podsadecki; Y-L Chiu; S Dutta; W M Awni
Journal:  Br J Clin Pharmacol       Date:  2016-02-24       Impact factor: 4.335

7.  Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in hepatitis C virus genotype 1 infection: analysis of six phase III trials.

Authors:  Sven Mensing; Doerthe Eckert; Shringi Sharma; Akshanth R Polepally; Amit Khatri; Thomas J Podsadecki; Walid M Awni; Rajeev M Menon; Sandeep Dutta
Journal:  Br J Clin Pharmacol       Date:  2016-11-03       Impact factor: 4.335

8.  No difference between direct-acting antivirals for hepatitis C in hepatocellular carcinoma risk.

Authors:  Elijah J Mun; Pamela Green; Kristin Berry; George N Ioannou
Journal:  Eur J Gastroenterol Hepatol       Date:  2019-01       Impact factor: 2.566

9.  Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Patients with Hepatitis C Virus Genotype 1 Infection: Combined Analysis from 9 Phase 1b/2 Studies.

Authors:  Sven Mensing; Akshanth R Polepally; Denise König; Amit Khatri; Wei Liu; Thomas J Podsadecki; Walid M Awni; Rajeev M Menon; Sandeep Dutta
Journal:  AAPS J       Date:  2015-11-23       Impact factor: 4.009

Review 10.  Pharmacologic Considerations in the Treatment of Hepatitis C Virus in Persons With HIV.

Authors:  Christine E MacBrayne; Jennifer J Kiser
Journal:  Clin Infect Dis       Date:  2016-07-15       Impact factor: 9.079
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.